Loading…
Editas Medicine, Inc. is projected to rise to $3.54 by 2027, a +8% move from its current price of $3.26. EDIT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $3.11 | $3.26 | $3.42 | +0.06% |
| Jul 13 | $3.05 | $3.26 | $3.49 | +0.11% |
| Jul 14 | $3.00 | $3.27 | $3.55 | +0.17% |
| Jul 15 | $2.97 | $3.27 | $3.60 | +0.22% |
| Jul 16 | $2.93 | $3.27 | $3.64 | +0.28% |
| Jul 17 | $2.91 | $3.27 | $3.68 | +0.34% |
| Jul 18 | $2.88 | $3.27 | $3.72 | +0.39% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.88 | $3.27 | $3.72 | +0.39% |
| Week 2 | $2.74 | $3.29 | $3.94 | +0.79% |
| Week 3 | $2.64 | $3.30 | $4.12 | +1.18% |
| Week 4 | $2.56 | $3.31 | $4.28 | +1.58% |
| Week 5 | $2.50 | $3.32 | $4.43 | +1.98% |
| Week 6 | $2.44 | $3.34 | $4.57 | +2.38% |
| Week 7 | $2.39 | $3.35 | $4.70 | +2.78% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Editas Medicine, Inc. is a clinical stage genome editing company focused on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology.
Its lead program EDIT-401 is a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia.
The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease.
Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts. It was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013.
Editas Medicine, Inc. (EDIT) trades in the Healthcare sector and is currently priced at $3.30.
The market capitalization is $506.42M and the stock ranks 3049. These figures place Editas within a broad market tier as a biotechnology name with a focused genome editing agenda.
Longer-term, the forecast implies upside through 2050, with 2026 average price of $3.30, 2027 of $3.58, 2028 of $5.29, 2029 of $7.27, 2030 of $7.12, 2031 of $7.91, 2032 of $8.33, 2033 of $8.10, 2034 of $11.72, 2035 of $13.84, 2040 of $21.65 and 2050 of $36.19. The corresponding ROI figures rise from 0 in 2026 to 996.8 by 2050, with sentiment upgrading to BULLISH in later years after 2027.
A major floor 46.8% below — a decisive break under it would weaken the trend.
The nearest floor, 27.6% below — buyers have tended to step in here.
The nearest ceiling, 15.0% above — a clean break opens room to run.
A major ceiling 38.4% above — clearing it would confirm fresh momentum.
Key EDIT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of EDIT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.53 | Sell | $3.41 | Sell |
| MA 10 | $3.39 | Sell | $3.33 | Sell |
| MA 20 | $3.00 | Buy | $3.16 | Buy |
| MA 50 | $2.95 | Buy | $2.98 | Buy |
| MA 100 | $2.74 | Buy | $2.82 | Buy |
| MA 200 | $2.70 | Buy | $2.71 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.71 | Neutral |
| Stoch RSI (14) | 22.78 | Neutral |
| CCI (20) | 43.51 | Neutral |
| Williams %R (14) | -48.51 | Info |
| MACD (12,26,9) | 0.05 | Buy |
| ROC (12) | 18.12 | Buy |
| Bollinger %B (20,2) | 0.65 | Neutral |
| Stochastic %K (14) | 51.49 | Neutral |
| TRIX (15) | 0.63 | Buy |
| Awesome (5,34) | 0.55 | Buy |
| Ultimate (7,14,28) | 54.84 | Neutral |
| Momentum (10) | 0.52 | Buy |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 3.50 | Sell |
| ADX (14) | 19.93 | Neutral |
| ATR (14) | 0.13 | Info |
The 30-day technical picture for EDIT is BULLISH. The RSI14 reading is 60.
The SMA50 is $2.94 and the SMA200 is $2.70, signaling price support near the mid-$2s and a rising longer-term trend.
Key levels to watch are support at $2.36 and resistance at $3.75, with a 30-day price range of $2.38 to $4.58.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.66 | $3.26 | $4.49 | 0% | Neutral | |
| $2.61 | $3.54 | $5.16 | +8% | Neutral | |
| $3.63 | $5.19 | $8.03 | +59% | Bullish | |
| $4.76 | $7.12 | $11.54 | +118% | Bullish | |
| $4.48 | $6.98 | $11.75 | +114% | Bullish | |
| $4.79 | $7.75 | $13.47 | +138% | Bullish | |
| $4.88 | $8.20 | $14.65 | +151% | Bullish | |
| $4.58 | $7.98 | $14.63 | +145% | Bullish | |
| $6.36 | $11.45 | $21.51 | +251% | Bullish | |
| $7.26 | $13.51 | $25.93 | +314% | Bullish | |
| $9.66 | $21.05 | $44.17 | +546% | Bullish | |
| $16.00 | $35.56 | $81.79 | +991% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.66 | $3.26 | $4.22 | +0.00% |
| August 2026 | $2.94 | $3.55 | $4.44 | +8.82% |
| September 2026 | $2.81 | $3.43 | $4.38 | -3.29% |
| October 2026 | $2.83 | $3.50 | $4.54 | +2.00% |
| November 2026 | $2.88 | $3.59 | $4.71 | +2.45% |
| December 2026 | $2.68 | $3.37 | $4.49 | -5.88% |
Click any year to see its month-by-month EDIT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect EDIT to range from $1.66 to $4.49 through 2026. The $3.26 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The EDIT price prediction for 2027 points to an average of $3.54 (low $2.61, high $5.16) — a potential gain of +8% on today's $3.26. Price action looks broadly range-bound.
In 2028, EDIT is projected to trade between $3.63 and $8.03, averaging $5.19 — a potential gain of +59% from today's $3.26. That is up +47% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Editas Medicine, Inc.'s 2029 outlook centres on $7.12, within a $4.76 to $11.54 range. That is up +37% on the projected 2028 average. That marks a +118% change versus current levels. Momentum favours further upside here.
By 2030, EDIT could reach as high as $11.75, with a base case around $6.98 and support toward $4.48 — roughly +114% from $3.26. Buyers look set to stay in control over this stretch.
Expect EDIT to range from $4.79 to $13.47 through 2031. The $7.75 average target implies a +138% move from current prices. That is up +11% on the projected 2030 average. Momentum favours further upside here.
The EDIT price prediction for 2032 points to an average of $8.20 (low $4.88, high $14.65) — a potential gain of +151% on today's $3.26. Buyers look set to stay in control over this stretch.
In 2033, EDIT is projected to trade between $4.58 and $14.63, averaging $7.98 — a potential gain of +145% from today's $3.26. That is -3% versus the projected 2032 average. Momentum favours further upside here.
Editas Medicine, Inc.'s 2034 outlook centres on $11.45, within a $6.36 to $21.51 range. That is up +44% on the projected 2033 average. That marks a +251% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, EDIT could reach as high as $25.93, with a base case around $13.51 and support toward $7.26 — roughly +314% from $3.26. Momentum favours further upside here.
Expect EDIT to range from $9.66 to $44.17 through 2040. The $21.05 average target implies a +546% move from current prices. That is up +56% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The EDIT price prediction for 2050 points to an average of $35.56 (low $16.00, high $81.79) — a potential gain of +991% on today's $3.26. Momentum favours further upside here.
Investing $1,000 in EDIT today (≈ 306.748466 EDIT) could be worth
$10,907.95
+$9,907.95 (+991%) by 2050 · US Dollar
Based on the average projected EDIT price of $35.56 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in EDITwould be worth at today's price.
$1,000 invested in EDIT on Jul 10, 2025 (≈ 326.797392 EDIT) would be worth
$1,065.36
+$65.36 (+6.5%) today · 1.07× · US Dollar
Based on a EDIT entry price of $3.06 vs. today's $3.26.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.65 | $893.15 | -10.7% |
| 1 month ago | $2.48 | $1,314.52 | +31.5% |
| 3 months ago | $2.94 | $1,108.84 | +10.9% |
| 6 months ago | $2.13 | $1,530.52 | +53.1% |
| 1 year ago | $3.06 | $1,065.36 | +6.5% |
| All time (5.0y) ago | $46.07 | $70.76 | -92.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our EDIT forecast.
Our base-case forecast reaches $6.50 around 2029.
Implied market cap at $6.50: $997.5M
The multi-year forecast points to a bullish trajectory for EDIT, with average prices climbing from $3.30 in 2026 to $36.19 in 2050 and ROI expanding to 996.8 by 2050.
2030 stands out with an average of $7.12 and ROI of 115.9, supported by a BULLISH sentiment. This reflects a meaningful uplift from the 2026 base and an ongoing upside path into the next decade.
2040 shows substantial growth with an average of $21.65 and ROI of 556, while 2050 shows an average of $36.19 and ROI of 996.8, both labeled BULLISH. These projections illustrate a long-run uptrend, albeit with inherent forecasting uncertainty and the usual risks associated with equity outcomes in the biotechnology sector.
These are estimates, not guarantees, and actual results may differ."
Tap a question to reveal the answer.
2030 avg price $7.12; max $12.10; ROI 115.9; sentiment BULLISH.
Forecasts show upside through 2050, with 2034 avg $11.72, 2040 avg $21.65 and 2050 avg $36.19; 2026 avg $3.30 with ROI 0 and NEUTRAL sentiment, trending bullish later. These are estimates, not guarantees.
The forecast max for 2050 is $83.24, so $100 is not indicated by the provided numbers.
Current price is $3.30; market cap is $506.42M.
RSI14 is 60; sentiment is BULLISH. SMA50 is $2.94 and SMA200 is $2.70. Support is $2.36 and resistance is $3.75. The 30-day range is $2.38 to $4.58.
Editas Medicine, Inc. Community Discussion
0Share your Editas Medicine, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.